Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma
JCO Precision Oncology · 2024
DOI: 10.1200/po.24.00167 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Carol Cremin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Genetic Testing, Pancreatic Neoplasms, Health Services Accessibility. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Approximately 5%-10% of patients with pancreatic ductal adenocarcinoma (PDAC) have an inherited basis, yet uptake of genetic testing remains low and subject to disparities. This study compared two genetic testing pathways available to patients referred to a provincial cancer center, BC Cancer: a traditional hereditary cancer clinic–initiated testing (HCT) pathway and a new oncology clinic–initiated testing (OCT) pathway. METHODS Study subjects were patients with confirmed PDAC referred for genetic testing through the HCT or OCT pathway between June 1, 2020, and February 1, 2022. Charts were retrospectively reviewed for patient characteristics and testing outcomes. RESULTS The study population was 397 patients (HCT, n = 279 and OCT, n = 118). OCT patients were more likely to have non-European ethnicity compared with HCT patients (41.9% v 25.6%, P = .004), to have earlier-stage disease ( P = .012), and to have better Eastern Cooperative Oncology Group performance status than the HCT group ( P = .001). A total of 306 patients completed testing (77%). OCT patients had higher test completion rates than HCT patients (odds ratio, 3.74 [95% CI, 1.66 to 9.62]). Median time for results was shorter in OCT than in HCT (53 days [IQR, 44-76] v 107 days [IQR, 63.8-158.3]). Pancreatic cancer susceptibility pathogenic gene variants were identified in 8.5% (26/306). CONCLUSION The real-world observations in our study show that oncology clinic–initiated hereditary testing is more effective and faster than testing through hereditary cancer clinic referrals and reaches a more ethnically diverse population. This has important implications for publicly funded environments with limited resources for genetic counseling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada.
- Pancreas Centre BC, Vancouver, BC, Canada.
- Department of Medical Genetics, The University of British Columbia, Vancouver, BC, Canada.
- Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
- Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
- Division of Anatomical Pathology, Vancouver General Hospital, Vancouver, BC, Canada.
ORCID-Profile: Carol Cremin, Angela C Bedard, Quan Hong, Sophie Sun, Kasmintan A Schrader
Zitieren
APA
Cremin, C., Bedard, A. C., Hong, Q., Mung, S. W., Nuk, J., Wong, A., Akbar, H., Cheung, E., Renouf, D., Schaeffer, D., Sun, S., & Schrader, K. A. (2024). Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma. JCO Precision Oncology. https://doi.org/10.1200/po.24.00167
Vancouver
Cremin C, Bedard AC, Hong Q, Mung SW, Nuk J, Wong A, et al. Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma. JCO Precision Oncology. 2024. doi:10.1200/po.24.00167
BibTeX
@article{Cremin2024,
author = {Cremin, Carol and Bedard, Angela C and Hong, Quan and Mung, Sze Wing and Nuk, Jennifer and Wong, Andrew and Akbar, Husain and Cheung, Eugene and Renouf, Daniel and Schaeffer, David and Sun, Sophie and Schrader, Kasmintan A},
title = {Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.24.00167}
}
EUVIMED